Manila Times Business
Enable Injections Announces CE Certification of the enFuse® On-Body Delivery System for Use with Aspaveli® Distributed by Sobi
Regulatory milestone expands access to wearable, patient-centric drug delivery for rare disease treatment across Europe CINCINNATI, May 22, 2026 (GLOBE NEWSWIRE) -- Enable Injections, Inc. ("Enable”), a healthcare innovation company developing and manufacturing the enFuse® On-Body Delivery System (OBDS), today announced CE Certification of its enFuse on-body injector and syringe transfer system for use in combination with Aspaveli® (pegcetacoplan). The enFuse OBDS will be commercialized as ASPAV
This is an excerpt. Read the full article at the original source:
Source: manilatimes.net
Read Full Article on manilatimes.net →More from Manila Times Business
Mineralys Therapeutics Presents New Data from the Phase 3 Launch-HTN Trial of Lorundrostat in Participants with Hypertension and Chronic Kidney Disease at European Meeting on Hypertension and Cardiovascular Protection (ESH 2026)
1h ago
Ghana's 'anti-LGBTQ' law triggers both praise and outrage
2h ago
WHO chief visits epicentre of Ebola outbreak in DR Congo
2h ago
Vapofil Reviews [URGENT REPORT 2026] The Shocking VapoFil Male Enhancement Supplement Trend Everyone Is Talking About
2h ago